Edition:
United States

DURECT Corp (DRRX.OQ)

DRRX.OQ on NASDAQ Stock Exchange Global Market

1.12USD
16 Feb 2018
Change (% chg)

-- (--)
Prev Close
$1.12
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
187,115
52-wk High
$2.17
52-wk Low
$0.74

Select another date:

Wed, Nov 1 2017

BRIEF-Durect reports Q3 earnings per share of ‍$0.04​

* Durect Corporation announces third quarter 2017 financial results and provides corporate update

BRIEF-Durect announces top-line results from the persist phase 3 trial of Posimir® did not meet primary efficacy endpoint

* Durect announces top-line results from the persist phase 3 trial of Posimir® (saber®-bupivacaine) did not meet primary efficacy endpoint

BRIEF-Indivior says ‍durect, co sign $17.5 mln patent purchase deal

* DURECT AND INDIVIOR PLC SIGN A $17.5 MILLION PATENT PURCHASE AGREEMENT​

BRIEF-Durect appoints Myriam Theeuwes as senior vice president of clinical development

* Durect appoints Dr. Myriam Theeuwes as senior vice president, clinical development Source text for Eikon: Further company coverage:

Select another date: